Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User seeks reputable international finasteride seller due to dermatologists refusing prescription. Dermatologists suggested PRP or exosomes instead.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation is a satirical discussion about hair loss treatments, jokingly suggesting using a Cocker Spaniel as an alternative to actual treatments like finasteride, minoxidil, RU58841, ketoconazole, and dermarolling.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

The user switched to oral dutasteride and minoxidil and is questioning the need for derma stamping, which is typically used with topical treatments. They are considering whether derma stamping is necessary with their current oral regimen.

A user added sandalore to minoxidil for hair loss, observing some vellus hair growth and less scalp inflammation. Others tried sandalore with mixed results, discussing dosage and effectiveness compared to minoxidil and finasteride.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

ScottMills3 shared how to quickly get a prescription for generic Dutasteride (Dut .5mg) online through MedicalWellnessCenter, which cost $69.95 for the consultation and $31 for a 90-day supply. Another user suggested hidrb.com as a cheaper alternative, offering the same prescription for $15.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

A user is seeking a prescription for DUT (Dutasteride) after limited success with finasteride and minoxidil for hair loss. They are advised to explore telehealth services for potential prescriptions.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

People are discussing if Serioxyl / Stemoxydine sold on eBay is authentic and questioning how sellers have it if L'Oreal may not be producing it anymore. They are sharing experiences and seeking insight on the legitimacy of the product and its availability.

The conversation is about someone's 13-month hair regrowth progress using 0.5 mg Dutasteride daily, 5% Minoxidil twice daily, Biotin tablets, and Sebizole shampoo. They are happy with the results.

Using dermaneedling or dermapen for hair loss while managing seborrheic dermatitis and dandruff. Treatments mentioned include ketoconazole, peppermint and jojoba oil, and rubbing alcohol.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.